Results 141 to 150 of about 2,481 (285)

Changes in the cortical GABAergic inhibitory system with ageing and ageing‐related neurodegenerative diseases

The Journal of Physiology, EarlyView.
Abstract figure legend With ageing and age‐related neurodegenerative diseases, the amount of GABA and GABAergic inhibition as well as the modulation (indicated by sine wave) of GABAergic inhibition is reduced, whereas excitation is increased. In many parts of the brain, this leads to a mismatch of facilitatory (green neurons) and inhibitory (red ...
Wolfgang Taube, Benedikt Lauber
wiley   +1 more source

Spinal muscular atrophy–type I

Archives of Disease in Childhood, 2003
M. Hardart, R. Truog
semanticscholar   +1 more source

Exploring neuronal mechanisms of osteosarcopenia in older adults

The Journal of Physiology, EarlyView.
Abstract figure legend The mechanosensitive osteocytic network within the bone matrix acts as a receptor and plays a crucial role in the functional adaptation of bone to mechanical loading. Through mechanotransduction, osteocytes convert mechanical impulses into electrical signals, which are transmitted via afferent nerves to sympathetic preganglionic ...
Ilhan Karacan, Kemal Sıtkı Türker
wiley   +1 more source

Treatment acceptability for disease‐modifying therapy for type 1 diabetes (T1D)—Views from parents of children with presymptomatic T1D

Diabetes, Obesity and Metabolism, EarlyView.
Lauren M. Quinn, Olga Boiko, Josephine Elliott, Matthew Randell, Ian Litchfield, Felicity Boardman, Renuka P. Dias, Sheila M. Greenfield, Parth Narendran   +8 more
wiley   +1 more source

Update and new advances in fertility preservation and cancer

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Adolescents and young adults with a cancer diagnosis face unique challenges during treatment and into survivorship related to fertility and family building. This review provides an updated overview of the impact of cancer and its associated treatments, including novel treatments in male and female fertility.
Gwendolyn P. Quinn, Michelle Bayefsky, Brooke Cherven, Lauren V. Ghazal, Kara N. Goldman, Nina Francis Levin, Leena Nahata, Bobby Najari, Sameer Thakker, Daniel R. Greenberg, Joshua A. Halpern, Susan T. Vadaparampil   +11 more
wiley   +1 more source

FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making

Clinical Pharmacology &Therapeutics, Volume 118, Issue 3, Page 649-661, September 2025.
Real‐World Evidence (RWE) is increasingly used in submissions to regulatory agencies and health technology assessment bodies (HTAbs) to support the efficacy and effectiveness of new medicines and indications. However, there is limited information on the RWE characteristics that impact its role in approval and reimbursement decisions.
Gianmario Candore, Claire Martin, Mack J. Mills, Annabel Suter, Anna Lloyd, Danitza Chavez‐Montoya, Diego Civitelli, Birgit Wolf, Paul Bolot, Juergen Wasem, Montse Soriano Gabarró, Panos G. Kanavos, Mark Sculpher   +12 more
wiley   +1 more source

Mitochondrial Dysfunction in Aging: Future Therapies and Precision Medicine Approaches

MedComm – Future Medicine, Volume 4, Issue 3, September 2025.
Mitochondria play a critical role in aging and aging‐related diseases. This review systematically explores the mechanisms underlying mitochondrial deterioration during aging and highlights innovative therapeutic strategies for these mitochondrial problems.
Lanlan Jia, Ziyu Wei, Jinyuan Luoqian, Xi Wang, Chao Huang   +4 more
wiley   +1 more source

Evaluating the Effects of Nusinersen Treatment in Adults With Spinal Muscular Atrophy Using Axonal Excitability and MscanFit MUNE

Muscle &Nerve, Volume 72, Issue 3, Page 515-519, September 2025.
ABSTRACT Introduction/Aims The biological changes in motor neurons and motor axons that correlate with the clinical benefits of nusinersen, an antisense oligonucleotide, in spinal muscular atrophy (SMA) remain poorly understood. This study aimed to investigate changes in axonal excitability and motor unit number estimation (MUNE) parameters following a
Abir Alaamel, Nazan Şimşek Erdem, Gökçe Yağmur Güneş Gencer, Hüseyin Can Kaya, Hilmi Uysal   +4 more
wiley   +1 more source

Primary Progressive Multiple Sclerosis: New Therapeutic Approaches

Neuropsychopharmacology Reports, Volume 45, Issue 3, September 2025.
Primary progressive MS affects 10%–15% of MS patients, causing irreversible neurological impairment. Drugs like ocrelizumab show promise, while high‐dose biotin, simvastatin, and coenzyme Q10 are under investigation. Gene therapy and stem cell treatments also show potential.
Morteza Rajabi, Sajjad Shafaeibajestan, Sevda Asadpour, Ghazal Alyari, Niloofar Taei, Moein Kohkalani, Ramin Raoufinia, Hamed Afarande, Ehsan Saburi   +8 more
wiley   +1 more source

Never Late: Cerebrotendinous Xanthomatosis and Improvements in Neurocognitive Functions in an Adult Patient on Chenodeoxycholic Acid Treatment

Clinical Genetics, Volume 108, Issue 3, Page 363-368, September 2025.
Cerebrotendinous xanthomatosis is due to biallelic pathogenic variants in CYP27A1. We report a new patient and his good neurocognitive outcome on the chenodeoxycholic acid treatment despite therapy starting at the age of 34 years. This highlights the importance of recognizing treatable inherited metabolic diseases at any age.
Randa Sultan, Marta Villa‐Lopez, Clara Hung, Morganne McCabe, Oksana Suchowersky, Jordan Urlacher, Saadet Mercimek‐Andrews   +6 more
wiley   +1 more source